Contribute Try STAT+ Today

Is the Trump administration siding with consumer groups over drug makers in the fight over patient access and patent rights?

The US trade representative on Friday released its annual 301 Watch List, which identifies and ranks countries based on their willingness to protect intellectual property. The annual list is of great concern to drug makers, which argue that some countries fail to sufficiently protect and enforce patent rights. As a result, they complain that revenues are hurt and innovation is discouraged.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The headline doesn’t seem to quite go with the article? Seems like it should read, “is Trump admin siding with pharma?” since the 301 list is unchanged.

    • Hi Spring Texan,

      Thanks for writing. I agree that, since the 301 list is unchanged, it would not please consumer advocates. On the other hand, some appear to have expected the Trump administration to be less accepting of the TRIPS agreement. On that basis, there seems to be a pleasant surprise. And as the headline notes, its just one surprise.

      Hope that helps,
      ed at pharmalot

Comments are closed.